Adcendo
PrivateLast Round
Series C
Apr 14, 2026
Est. Valuation
$332,367
Total Funding Raised
$324.71M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Adcendo is a biotechnology company that develops antibody-drug conjugates aimed at creating innovative treatments for cancer patients facing significant unmet medical needs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adcendo Comparables
Compare Adcendo with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adcentrx Therapeutics | 83% | |
| Byondis | 82% | |
| Pheon Therapeutics | 80% |
Adcendo Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 14, 2026 | ||||
| Series B | Nov 25, 2024 | ||||
| Series A Extension | May 29, 2024 | ||||
| Series A Extension | Apr 4, 2023 | ||||
| Series A | Apr 29, 2021 | ||||
Convertible Debt | Aug 29, 2019 |
Key People
Founding team and executive leadership
Adcendo Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series C, Series B |
| RA Capital Management | Series A, Series A Extension, Series C, Series B |
| TCG Crossover | Series C, Series B |
| Kohlberg Kravis Roberts | Series C |
| Novo Nordisk Foundation | Grant |
| Ysios Capital | Series A Extension, Series C, Series B, Series A |
| Pontifax Venture Capital | Series A Extension, Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 30% MoM, reaching 4.7K.
- Jun 18, 2026
Monthly visitors grew 91% MoM, reaching 3.6K.
Adcendo Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Adcendo's valuation, stock price, and market status.
Is Adcendo a public or private company?
Adcendo is a private company.
What is the current stock price of Adcendo?
Adcendo is a private company with no public stock price. No recent secondary market data is available.
How much is Adcendo worth (valuation)?
Adcendo's valuation is estimated at $332.4K based on funding round data.
Can I buy Adcendo stock?
Adcendo shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Adcendo's last funding round?
Adcendo's most recent funding round was Series C on November 3, 2017.
Who are the main investors in Adcendo?
Key investors in Adcendo include TCG Crossover, Ysios Capital, Pontifax Venture Capital, Pontifax Credit, HealthCap.
Will Adcendo IPO soon?
No public IPO plans have been announced for Adcendo.
How can I track Adcendo secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Adcendo's secondary market activity and sign up for updates.